3.7M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 136,000 | 1,077,115 (2%) | 0% | 0 | Common Stock | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 196,000 | 196,000 | - | - | Stock Option (right to buy) | |
| James Basta | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 8.99 per share. | 01 Mar 2025 | 2,572 | 111,925 (0%) | 0% | 9.0 | 23,122 | Common Stock |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 40,000 | 114,497 (0%) | 0% | 0 | Common Stock | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 57,143 | 57,143 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 61,714 | 61,714 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,200 | 130,866 (0%) | 0% | 0 | Common Stock | |
| Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 67,429 | 67,429 | - | - | Stock Option (right to buy) | |
| Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 47,200 | 113,524 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 45,714 | 45,714 | - | - | Stock Option (right to buy) | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 32,000 | 96,048 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 8.99 per share. | 01 Mar 2025 | 679 | 95,369 (0%) | 0% | 9.0 | 6,104 | Common Stock |
| Michael P. Dube | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 14,000 | 59,640 (0%) | 0% | 0 | Common Stock | |
| Birgit Schultes | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 37,600 | 105,215 (0%) | 0% | 0 | Common Stock | |
| Birgit Schultes | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 53,714 | 53,714 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 9.97 per share. | 29 Jan 2025 | 265 | 19,468 (0%) | 0% | 10.0 | 2,642 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 26,807 | 941,115 (1%) | 0% | 12.2 | 326,509 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 8,966 | 77,388 (0%) | 0% | 12.2 | 109,206 | Common Stock |
| James Basta | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 7,074 | 74,497 (0%) | 0% | 12.2 | 86,161 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 9,557 | 87,666 (0%) | 0% | 12.2 | 116,404 | Common Stock |
| Derek Hicks | EVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 6,502 | 59,878 (0%) | 0% | 12.2 | 79,194 | Common Stock |
| Michael P. Dube | VP, Chief Accounting Officer | 03 Jan 2025 | 1,372 | 45,640 (0%) | 0% | 12.2 | 16,711 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 02 Jan 2025 | 7,422 | 64,048 (0%) | 0% | 12.2 | 90,400 | Common Stock |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 02 Jan 2025 | 556 | 71,470 (0%) | 0% | 12.0 | 6,689 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 967,922 (1%) | 0% | - | Common Stock | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 0 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,500 | 86,354 (0%) | 0% | - | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,500 | 0 | - | - | Restricted Stock Unit | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,189 | 0 | - | - | Restricted Stock Unit | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 3,189 | 97,223 (0%) | 0% | - | Common Stock | |
| Michael P. Dube | VP, Chief Accounting Officer | 02 Oct 2024 | 2,012 | 47,012 (0%) | 0% | 19.0 | 38,248 | Common Stock | |
| Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 96,219 | 96,219 | - | - | Stock Option (right to buy) | |
| Edward J. Dulac | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 66,324 | 66,324 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 22.93 per share. | 01 Jul 2024 | 405 | 71,470 (0%) | 0% | 22.9 | 9,287 | Common Stock |
| Michael P. Dube | VP, PAO and Interim PFO | 01 Jul 2024 | 17,801 | 49,024 (0%) | 0% | 0 | Common Stock | ||
| Frank Verwiel | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 17 Jun 2024 | 1,505 | 17,948 (0%) | 0% | 25 | 37,625 | Common Stock |
| Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 22,297 | 22,297 | - | - | Stock Option (right to buy) | |
| Brian Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 15,409 | 15,409 (0%) | 0% | 0 | Common Stock | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 49,453 (0%) | 0% | 0 | Common Stock | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 19,453 (0%) | 0% | 0 | Common Stock | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 26,693 (0%) | 0% | 0 | Common Stock | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 19,453 (0%) | 0% | 0 | Common Stock | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 23,883 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 19,733 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 163,929 | 163,929 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 113,586 | 960,072 (1%) | 0% | 0 | Common Stock | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 41,316 | 41,316 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 28,628 | 69,213 (0%) | 0% | 0 | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 37,966 | 81,893 (0%) | 0% | 0 | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 54,794 | 54,794 | - | - | Stock Option (right to buy) | |
| James Basta | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 32.99 per share. | 01 Mar 2024 | 2,297 | 81,571 (0%) | 0% | 33.0 | 75,778 | Common Stock |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 32,394 | 83,868 (0%) | 0% | 0 | Common Stock | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,752 | 46,752 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 38,701 | 93,073 (0%) | 0% | 0 | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 55,855 | 55,855 | - | - | Stock Option (right to buy) | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 42,421 | 42,421 | - | - | Stock Option (right to buy) | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 29,393 | 66,380 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 45,072 | 45,072 | - | - | Stock Option (right to buy) | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,230 | 72,075 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 32.99 per share. | 01 Mar 2024 | 605 | 71,470 (0%) | 0% | 33.0 | 19,959 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.66 per share. | 08 Jan 2024 | 1,608 | 44,594 (0%) | 0% | 28.7 | 46,085 | Common Stock |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.38 per share. | 08 Jan 2024 | 667 | 43,927 (0%) | 0% | 29.4 | 19,596 | Common Stock |
| Clark Eliana | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 4,301 | 40,845 (0%) | 0% | 29.5 | 126,707 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 5,843 | 54,372 (0%) | 0% | 29.5 | 172,135 | Common Stock |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 5,532 | 46,202 (0%) | 0% | 29.5 | 162,973 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 5,365 | 40,585 (0%) | 0% | 29.5 | 158,053 | Common Stock |
| Derek Hicks | EVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 3,877 | 36,987 (0%) | 0% | 29.5 | 114,216 | Common Stock |
| M. John Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 19,223 | 846,486 (1%) | 0% | 29.5 | 566,310 | Common Stock |
| Basta James | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 3,805 | 51,474 (0%) | 0% | 29.5 | 112,095 | Common Stock |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 30.12 per share. | 03 Jan 2024 | 307 | 45,146 (0%) | 0% | 30.1 | 9,247 | Common Stock |
| Leonard John M. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 7,850 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,500 | 3,500 | - | - | Restricted Stock Unit | |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,500 | 51,734 (0%) | 0% | - | Common Stock | |
| Lebwohl David | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,187 | 60,215 (0%) | 0% | - | Common Stock | |
| Goddard Glenn | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,062 | 45,950 (0%) | 0% | - | Common Stock | |
| Goddard Glenn | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,062 | 3,064 | - | - | Restricted Stock Unit | |
| Lebwohl David | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 3,187 | 3,189 | - | - | Restricted Stock Unit | |
| M. Leonard John | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 865,709 (1%) | 0% | - | Common Stock | |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 42.33 per share. | 31 Jul 2023 | 265 | 12,261 (0%) | 0% | 42.3 | 11,217 | Common Stock |
| Muna Bhanji | Director | Sale of securities on an exchange or to another person at price $ 39.30 per share. | 06 Jul 2023 | 1,867 | 12,526 (0%) | 0% | 39.3 | 73,373 | Common Stock |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 40.51 per share. | 03 Jul 2023 | 360 | 45,146 (0%) | 0% | 40.5 | 14,584 | Common Stock |
| Eliana Clark | EVP, Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.27 per share. | 20 Jun 2023 | 5,000 | 50,146 (0%) | 0% | 12.3 | 61,350 | Common Stock |
| Eliana Clark | EVP, Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 5,000 | 57,750 | - | - | Stock Option (right to buy) | |
| Eliana Clark | EVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 20 Jun 2023 | 5,000 | 45,146 (0%) | 0% | 45 | 225,000 | Common Stock |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 41,716 (0%) | 0% | 0 | Common Stock | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 11,716 (0%) | 0% | 0 | Common Stock | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 11,716 (0%) | 0% | 0 | Common Stock | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,447 | 2,447 | - | - | Stock Option (right to buy) | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 1,673 | 18,956 (0%) | 0% | 0 | Common Stock | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 11,716 (0%) | 0% | 0 | Common Stock | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 16,146 (0%) | 0% | 0 | Common Stock | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,473 | 6,473 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 4,425 | 14,393 (0%) | 0% | 0 | Common Stock | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 14,931 | 14,931 | - | - | Stock Option (Right to Buy) | |
| William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 10,483 | 17,283 (0%) | 0% | 0 | Common Stock | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 128,631 | 128,631 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 91,036 | 857,861 (1%) | 0% | 0 | Common Stock | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 38,834 | 38,834 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 27,484 | 42,888 (0%) | 0% | 0 | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 42,302 | 42,302 | - | - | Stock Option (right to buy) | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 29,938 | 47,567 (0%) | 0% | 0 | Common Stock | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 34,674 | 34,674 | - | - | Stock Option (right to buy) | |
| James Basta | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 43.88 per share. | 01 Mar 2023 | 1,088 | 55,279 (0%) | 0% | 43.9 | 47,741 | Common Stock |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 24,539 | 44,098 (0%) | 0% | 0 | Common Stock | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,269 | 56,367 (0%) | 0% | 0 | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 30,674 | 56,361 (0%) | 0% | 0 | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 43,342 | 43,342 | - | - | Stock Option (right to buy) | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 33,287 | 33,287 | - | - | Stock option (right to buy) | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 23,558 | 40,864 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 6,134 | 45,146 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 24,539 | 39,012 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 34,674 | 34,674 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 6,673 | 766,825 (1%) | 0% | 37.2 | 248,302 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 2,427 | 15,404 (0%) | 0% | 37.2 | 90,309 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 04 Jan 2023 | 1,641 | 18,318 (0%) | 0% | 38.2 | 62,719 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.10 per share. | 04 Jan 2023 | 689 | 17,629 (0%) | 0% | 39.1 | 26,940 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 2,508 | 19,959 (0%) | 0% | 37.2 | 93,323 | Common Stock |
| James Basta | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 1,138 | 19,559 (0%) | 0% | 37.2 | 42,345 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 2,574 | 25,687 (0%) | 0% | 37.2 | 95,779 | Common Stock |
| Derek Hicks | EVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 1,812 | 17,306 (0%) | 0% | 37.2 | 67,425 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 773,498 (1%) | 0% | - | Common Stock | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 15,698 | - | - | Restricted Stock Unit | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,062 | 6,126 | - | - | Restricted Stock Unit | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,062 | 17,831 (0%) | 0% | - | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,500 | 7,000 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,500 | 22,467 (0%) | 0% | - | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,187 | 6,376 | - | - | Restricted Stock Unit | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 3,187 | 28,261 (0%) | 0% | - | Common Stock | |
| Caroline D. Dorsa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Caroline D. Dorsa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 12,701 (0%) | 0% | 0 | Common Stock | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 37,291 (0%) | 0% | 0 | Common Stock | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 7,291 (0%) | 0% | 0 | Common Stock | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 7,291 (0%) | 0% | 0 | Common Stock | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 7,291 (0%) | 0% | 0 | Common Stock | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 7,291 (0%) | 0% | 0 | Common Stock | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 5,197 | 11,721 (0%) | 0% | 0 | Common Stock | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 7,688 | 7,688 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 2,980 | 2,980 | - | - | Stock Option (right to buy) | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 2,014 | 9,968 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 7,954 | 7,954 (0%) | 0% | 0 | Common Stock | |
| Muna Bhanji | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 11,700 | 11,700 | - | - | Stock Option (Right to Buy) | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,648 | 9,648 | - | - | Stock Option (right to buy) | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,049 | 11,049 (0%) | 0% | 0 | Common Stock | |
| James Basta | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,648 | 20,697 (0%) | 0% | 0 | Common Stock | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 15,395 | 15,395 | - | - | Stock Option (right to buy) | |
| Eliana Clark | EVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 10,527 | 16,165 (0%) | 0% | 0 | Common Stock | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 19,118 | 19,118 (0%) | 0% | 0 | Common Stock | |
| Derek Hicks | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 112.24 per share. | 01 Jan 2022 | 1,013 | 2,049 (0%) | 0% | 112.2 | 113,699 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 12,720 | 14,769 (0%) | 0% | 0 | Common Stock | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,062 | 9,188 | - | - | Restricted Stock Unit | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 12,720 | 12,720 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,062 | 3,062 (0%) | 0% | - | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,500 | 10,500 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 18,631 (0%) | 0% | 0 | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 112.25 per share. | 01 Jan 2022 | 1,148 | 4,815 (0%) | 0% | 112.3 | 128,863 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,500 | 5,963 (0%) | 0% | - | Common Stock | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 13,816 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 112.24 per share. | 01 Jan 2022 | 1,051 | 10,922 (0%) | 0% | 112.2 | 117,964 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 24,738 (0%) | 0% | 0 | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,187 | 9,563 | - | - | Restricted Stock Unit | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 13,816 | 13,816 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,187 | 11,973 (0%) | 0% | - | Common Stock | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 2,400 | 180,077 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 05 Nov 2021 | 2,400 | 11,114 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 131.71 per share. | 05 Nov 2021 | 1,200 | 9,914 (0%) | 0% | 131.7 | 158,052 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 132.62 per share. | 05 Nov 2021 | 452 | 9,462 (0%) | 0% | 132.6 | 59,944 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 134.07 per share. | 05 Nov 2021 | 548 | 8,914 (0%) | 0% | 134.1 | 73,470 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 135.34 per share. | 05 Nov 2021 | 200 | 8,714 (0%) | 0% | 135.3 | 27,068 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2021 | 2,400 | 182,477 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 126.92 per share. | 14 Oct 2021 | 551 | 10,563 (0%) | 0% | 126.9 | 69,933 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 14 Oct 2021 | 2,400 | 11,114 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 129.83 per share. | 14 Oct 2021 | 525 | 8,964 (0%) | 0% | 129.8 | 68,161 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 129.01 per share. | 14 Oct 2021 | 225 | 9,489 (0%) | 0% | 129.0 | 29,027 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 127.81 per share. | 14 Oct 2021 | 849 | 9,714 (0%) | 0% | 127.8 | 108,511 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 130.47 per share. | 14 Oct 2021 | 250 | 8,714 (0%) | 0% | 130.5 | 32,618 | Common Stock |
| John F. Crowley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2021 | 2,500 | 25,500 | - | - | Stock Option (right to buy) | |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 119.55 per share. | 11 Oct 2021 | 2,500 | 2,094 (0%) | 0% | 119.6 | 298,875 | Common Stock |
| John F. Crowley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.83 per share. | 11 Oct 2021 | 2,500 | 4,594 (0%) | 0% | 18.8 | 47,075 | Common Stock |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 128.83 per share. | 05 Oct 2021 | 1,280 | 10,814 (0%) | 0% | 128.8 | 164,902 | Common Stock |
| John F. Crowley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 10,000 | 28,000 | - | - | Stock Option (right to buy) | |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 132.84 per share. | 05 Oct 2021 | 200 | 2,094 (0%) | 0% | 132.8 | 26,568 | Common Stock |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 131.74 per share. | 05 Oct 2021 | 1,846 | 2,294 (0%) | 0% | 131.7 | 243,192 | Common Stock |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 130.92 per share. | 05 Oct 2021 | 3,759 | 4,140 (0%) | 0% | 130.9 | 492,128 | Common Stock |
| John F. Crowley | Director | Sale of securities on an exchange or to another person at price $ 129.88 per share. | 05 Oct 2021 | 2,915 | 7,899 (0%) | 0% | 129.9 | 378,600 | Common Stock |
| John F. Crowley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.83 per share. | 05 Oct 2021 | 10,000 | 12,094 (0%) | 0% | 18.8 | 188,300 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2021 | 7,923 | 184,877 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 24 Sep 2021 | 7,923 | 8,714 (0%) | 0% | 12.6 | 99,988 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 2,400 | 192,800 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 149.81 per share. | 21 Sep 2021 | 2,400 | 791 (0%) | 0% | 149.8 | 359,544 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 21 Sep 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 3,482 | 12,451 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 180.12 per share. | 07 Sep 2021 | 3,482 | 0 (0%) | 0% | 180.1 | 627,178 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 07 Sep 2021 | 3,482 | 3,482 (0%) | 0% | 14.6 | 50,768 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 37,833 | 90,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 27,167 | 127,833 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 11,637 | 212,501 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.00 per share. | 30 Aug 2021 | 44,735 | 719,305 (1%) | 0% | 170 | 7,604,950 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 30 Aug 2021 | 15,985 | 764,040 (1%) | 0% | 18.3 | 292,526 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.46 per share. | 30 Aug 2021 | 28,750 | 748,055 (1%) | 0% | 23.5 | 674,475 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.00 per share. | 30 Aug 2021 | 37,833 | 719,305 (1%) | 0% | 155 | 5,864,115 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 37,833 | 757,138 (1%) | 0% | 14.6 | 551,605 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 160.69 per share. | 30 Aug 2021 | 216 | 719,305 (1%) | 0% | 160.7 | 34,709 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.98 per share. | 30 Aug 2021 | 725 | 719,521 (1%) | 0% | 160.0 | 115,986 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.18 per share. | 30 Aug 2021 | 2,598 | 720,246 (1%) | 0% | 159.2 | 413,550 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 157.75 per share. | 30 Aug 2021 | 3,123 | 722,844 (1%) | 0% | 157.7 | 492,653 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 156.96 per share. | 30 Aug 2021 | 4,758 | 725,967 (1%) | 0% | 157.0 | 746,816 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.70 per share. | 30 Aug 2021 | 15,567 | 730,725 (1%) | 0% | 155.7 | 2,423,782 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 154.98 per share. | 30 Aug 2021 | 7,428 | 746,292 (1%) | 0% | 155.0 | 1,151,191 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.66 per share. | 30 Aug 2021 | 2,334 | 753,720 (1%) | 0% | 153.7 | 358,642 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 30 Aug 2021 | 11,637 | 730,942 (1%) | 0% | 13.4 | 155,936 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 27,167 | 758,109 (1%) | 0% | 14.6 | 396,095 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.81 per share. | 30 Aug 2021 | 2,055 | 756,054 (1%) | 0% | 152.8 | 314,025 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 15,985 | 11,515 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 28,750 | 0 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 30 Aug 2021 | 5,200 | 5,200 (0%) | 0% | 19.3 | 100,204 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 1,817 | 15,933 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 22,983 | 41,817 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 5,200 | 64,800 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.22 per share. | 30 Aug 2021 | 24,800 | 0 (0%) | 0% | 160.2 | 3,973,456 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 1,817 | 24,800 (0%) | 0% | 14.6 | 26,492 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 30 Aug 2021 | 22,983 | 22,983 (0%) | 0% | 19.3 | 442,882 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.84 per share. | 30 Aug 2021 | 300 | 0 (0%) | 0% | 160.8 | 48,252 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 159.53 per share. | 30 Aug 2021 | 300 | 300 (0%) | 0% | 159.5 | 47,859 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.42 per share. | 30 Aug 2021 | 300 | 600 (0%) | 0% | 158.4 | 47,526 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 157.33 per share. | 30 Aug 2021 | 496 | 900 (0%) | 0% | 157.3 | 78,036 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 156.10 per share. | 30 Aug 2021 | 300 | 1,396 (0%) | 0% | 156.1 | 46,830 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 155.29 per share. | 30 Aug 2021 | 1,700 | 1,696 (0%) | 0% | 155.3 | 263,993 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 154.29 per share. | 30 Aug 2021 | 1,100 | 3,396 (0%) | 0% | 154.3 | 169,719 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 153.22 per share. | 30 Aug 2021 | 704 | 4,496 (0%) | 0% | 153.2 | 107,867 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 70,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 155.61 per share. | 30 Aug 2021 | 16,115 | 18,123 (0%) | 0% | 155.6 | 2,507,655 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 156.79 per share. | 30 Aug 2021 | 7,425 | 10,698 (0%) | 0% | 156.8 | 1,164,166 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 157.77 per share. | 30 Aug 2021 | 3,932 | 6,766 (0%) | 0% | 157.8 | 620,352 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 158.90 per share. | 30 Aug 2021 | 1,515 | 5,251 (0%) | 0% | 158.9 | 240,734 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 159.64 per share. | 30 Aug 2021 | 2,653 | 2,598 (0%) | 0% | 159.6 | 423,525 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 160.47 per share. | 30 Aug 2021 | 207 | 2,391 (0%) | 0% | 160.5 | 33,217 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 27,000 | 82,000 | - | - | Stock Option (right to buy) | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 30 Aug 2021 | 27,000 | 29,391 (0%) | 0% | 13.4 | 361,800 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 30 Aug 2021 | 70,000 | 99,391 (0%) | 0% | 14.3 | 997,500 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 152.75 per share. | 30 Aug 2021 | 15,839 | 83,552 (0%) | 0% | 152.7 | 2,419,407 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 153.64 per share. | 30 Aug 2021 | 20,645 | 62,907 (0%) | 0% | 153.6 | 3,171,898 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 154.77 per share. | 30 Aug 2021 | 28,669 | 34,238 (0%) | 0% | 154.8 | 4,437,101 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 159.19 per share. | 30 Aug 2021 | 1,100 | 941 (0%) | 0% | 159.2 | 175,109 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 157.60 per share. | 30 Aug 2021 | 250 | 2,041 (0%) | 0% | 157.6 | 39,400 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 156.70 per share. | 30 Aug 2021 | 700 | 2,291 (0%) | 0% | 156.7 | 109,690 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 155.43 per share. | 30 Aug 2021 | 200 | 2,991 (0%) | 0% | 155.4 | 31,086 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 30 Aug 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 2,400 | 195,200 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 160.10 per share. | 30 Aug 2021 | 150 | 791 (0%) | 0% | 160.1 | 24,015 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.54 per share. | 23 Aug 2021 | 18,874 | 727,570 (1%) | 0% | 151.5 | 2,860,166 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 27,139 | 224,138 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.52 per share. | 23 Aug 2021 | 100 | 719,305 (1%) | 0% | 153.5 | 15,352 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.08 per share. | 23 Aug 2021 | 8,165 | 719,405 (1%) | 0% | 153.1 | 1,249,898 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 23 Aug 2021 | 27,139 | 746,444 (1%) | 0% | 13.4 | 363,663 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.56 per share. | 19 Aug 2021 | 6,993 | 725,268 (1%) | 0% | 151.6 | 1,059,859 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 22,682 | 251,277 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.30 per share. | 19 Aug 2021 | 5,963 | 719,305 (1%) | 0% | 152.3 | 908,165 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 150.46 per share. | 19 Aug 2021 | 9,726 | 732,261 (1%) | 0% | 150.5 | 1,463,374 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 19 Aug 2021 | 22,682 | 741,987 (1%) | 0% | 13.4 | 303,939 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 2,400 | 197,600 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 164.05 per share. | 09 Aug 2021 | 2,400 | 791 (0%) | 0% | 164.1 | 393,720 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 09 Aug 2021 | 2,400 | 3,191 (0%) | 0% | 12.6 | 30,288 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 151.41 per share. | 05 Aug 2021 | 9,568 | 530 (0%) | 0% | 151.4 | 1,448,691 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 152.13 per share. | 05 Aug 2021 | 530 | 0 (0%) | 0% | 152.1 | 80,629 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 20,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.27 per share. | 05 Aug 2021 | 20,000 | 20,000 (0%) | 0% | 19.3 | 385,400 | Common Stock |
| Glenn Goddard | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 150.65 per share. | 05 Aug 2021 | 9,902 | 10,098 (0%) | 0% | 150.6 | 1,491,736 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 141.63 per share. | 04 Aug 2021 | 126 | 2,391 (0%) | 0% | 141.6 | 17,845 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 26,000 | 109,000 | - | - | Stock Option (right to buy) | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 04 Aug 2021 | 26,000 | 28,391 (0%) | 0% | 13.4 | 348,400 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 135.47 per share. | 04 Aug 2021 | 1,471 | 26,920 (0%) | 0% | 135.5 | 199,276 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 136.79 per share. | 04 Aug 2021 | 6,814 | 20,106 (0%) | 0% | 136.8 | 932,087 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 137.72 per share. | 04 Aug 2021 | 6,344 | 13,762 (0%) | 0% | 137.7 | 873,696 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 138.78 per share. | 04 Aug 2021 | 4,419 | 9,343 (0%) | 0% | 138.8 | 613,269 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 139.85 per share. | 04 Aug 2021 | 2,772 | 6,571 (0%) | 0% | 139.8 | 387,664 | Common Stock |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 140.73 per share. | 04 Aug 2021 | 4,054 | 2,517 (0%) | 0% | 140.7 | 570,519 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 138.05 per share. | 28 Jun 2021 | 5,400 | 102,673 (0%) | 0% | 138.1 | 745,470 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 127.02 per share. | 28 Jun 2021 | 26,019 | 537,357 (1%) | 0% | 127.0 | 3,304,933 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 127.79 per share. | 28 Jun 2021 | 55,525 | 481,832 (0%) | 0% | 127.8 | 7,095,540 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 128.77 per share. | 28 Jun 2021 | 56,280 | 425,552 (0%) | 0% | 128.8 | 7,247,176 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 129.88 per share. | 28 Jun 2021 | 48,724 | 376,828 (0%) | 0% | 129.9 | 6,328,273 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 130.79 per share. | 28 Jun 2021 | 66,468 | 310,360 (0%) | 0% | 130.8 | 8,693,350 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 131.82 per share. | 28 Jun 2021 | 53,823 | 256,537 (0%) | 0% | 131.8 | 7,094,948 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 132.77 per share. | 28 Jun 2021 | 56,188 | 200,349 (0%) | 0% | 132.8 | 7,460,081 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 133.77 per share. | 28 Jun 2021 | 36,519 | 163,830 (0%) | 0% | 133.8 | 4,885,147 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 134.86 per share. | 28 Jun 2021 | 30,831 | 132,999 (0%) | 0% | 134.9 | 4,157,869 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 135.83 per share. | 28 Jun 2021 | 21,893 | 111,106 (0%) | 0% | 135.8 | 2,973,726 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 137.01 per share. | 28 Jun 2021 | 3,033 | 108,073 (0%) | 0% | 137.0 | 415,551 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 138.58 per share. | 28 Jun 2021 | 4,201 | 98,472 (0%) | 0% | 138.6 | 582,175 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 139.96 per share. | 28 Jun 2021 | 52,320 | 46,152 (0%) | 0% | 140.0 | 7,322,707 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 140.80 per share. | 28 Jun 2021 | 8,027 | 38,125 (0%) | 0% | 140.8 | 1,130,202 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 141.66 per share. | 28 Jun 2021 | 8,420 | 29,705 (0%) | 0% | 141.7 | 1,192,777 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 142.88 per share. | 28 Jun 2021 | 13,556 | 16,149 (0%) | 0% | 142.9 | 1,936,881 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 143.45 per share. | 28 Jun 2021 | 6,149 | 10,000 (0%) | 0% | 143.4 | 882,074 | Common Stock |
| Caroline D. Dorsa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Caroline D. Dorsa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Frank Verwiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Jesse Goodman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 3,382 | 3,382 | - | - | Stock Option (right to buy) | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 2,094 | 2,094 (0%) | 0% | 0 | Common Stock | |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 85.98 per share. | 11 Jun 2021 | 1,875 | 734,155 (1%) | 0% | 86.0 | 161,213 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 89.25 per share. | 11 Jun 2021 | 653 | 563,376 (1%) | 0% | 89.2 | 58,280 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 88.70 per share. | 11 Jun 2021 | 13,309 | 564,029 (1%) | 0% | 88.7 | 1,180,508 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 87.75 per share. | 11 Jun 2021 | 93,102 | 577,338 (1%) | 0% | 87.8 | 8,169,701 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 86.73 per share. | 11 Jun 2021 | 47,422 | 670,440 (1%) | 0% | 86.7 | 4,112,910 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 85.92 per share. | 11 Jun 2021 | 16,293 | 717,862 (1%) | 0% | 85.9 | 1,399,895 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 85.18 per share. | 11 Jun 2021 | 29,071 | 736,030 (1%) | 0% | 85.2 | 2,476,268 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 85.39 per share. | 26 Apr 2021 | 79,714 | 1,032,056 (2%) | 0% | 85.4 | 6,806,778 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 86.12 per share. | 26 Apr 2021 | 29,740 | 769,614 (1%) | 0% | 86.1 | 2,561,209 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 85.40 per share. | 26 Apr 2021 | 102,186 | 799,354 (1%) | 0% | 85.4 | 8,726,684 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 87.08 per share. | 26 Apr 2021 | 61,680 | 901,540 (1%) | 0% | 87.1 | 5,371,094 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 86.41 per share. | 26 Apr 2021 | 68,836 | 963,220 (1%) | 0% | 86.4 | 5,948,119 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 84.93 per share. | 26 Apr 2021 | 806 | 1,111,770 (2%) | 0% | 84.9 | 68,454 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 15,937 | 15,937 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 13 Apr 2021 | 15,937 | 719,305 (1%) | 0% | 13.9 | 221,206 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 13 Apr 2021 | 10,000 | 703,368 (1%) | 0% | 6.8 | 68,300 | Common Stock |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2021 | 4,955 | 4,955 (0%) | 0% | 0 | Common Stock | |
| Georgia Keresty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2021 | 7,755 | 7,755 | - | - | Stock Option (right to buy) | |
| Caroline D. Dorsa | Director | Sale of securities on an exchange or to another person at price $ 81.49 per share. | 05 Apr 2021 | 2,014 | 10,896 (0%) | 0% | 81.5 | 164,121 | Common Stock |
| Caroline D. Dorsa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.40 per share. | 05 Apr 2021 | 7,500 | 12,910 (0%) | 0% | 6.4 | 48,000 | Common Stock |
| Caroline D. Dorsa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 7,500 | 9,088 | - | - | Stock Option (right to buy) | |
| Caroline D. Dorsa | Director | Sale of securities on an exchange or to another person at price $ 82.99 per share. | 05 Apr 2021 | 800 | 5,410 (0%) | 0% | 83.0 | 66,392 | Common Stock |
| Caroline D. Dorsa | Director | Sale of securities on an exchange or to another person at price $ 82.35 per share. | 05 Apr 2021 | 4,686 | 6,210 (0%) | 0% | 82.3 | 385,892 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 84.98 per share. | 05 Apr 2021 | 800 | 1,112,576 (2%) | 0% | 85.0 | 67,984 | Common Stock |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 188,363 | 188,363 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 31,394 | 31,394 | - | - | Restricted Stock Unit | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 73,500 | 73,500 | - | - | Stock Option (right to buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 12,250 | 12,250 | - | - | Restricted Stock Unit | |
| Jose E. Rivera | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 12,250 | 12,250 | - | - | Restricted Stock Unit | |
| Jose E. Rivera | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 73,500 | 73,500 | - | - | Stock Option (right to buy) | |
| Andrew Schiermeier | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 78,750 | 78,750 | - | - | Stock Option (right to buy) | |
| Andrew Schiermeier | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 13,125 | 13,125 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 14,000 | 14,000 | - | - | Restricted Stock Unit | |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 84,000 | 84,000 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 76,500 | 76,500 | - | - | Stock Option (right to buy) | |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 12,750 | 12,750 | - | - | Restricted Stock Unit | |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 60.29 per share. | 26 Feb 2021 | 501,945 | 1,113,376 (2%) | 0% | 60.3 | 30,262,716 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 21,000 | 50,090 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 09 Feb 2021 | 11,489 | 117,920 (0%) | 0% | 75 | 861,675 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 09 Feb 2021 | 21,000 | 129,409 (0%) | 0% | 18.3 | 384,195 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 05 Feb 2021 | 40,000 | 654,803 (1%) | 0% | 13.4 | 536,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 56,718 | 68,516 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 40,000 | 285,453 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 05 Feb 2021 | 28,043 | 660,536 (1%) | 0% | 75 | 2,103,225 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 05 Feb 2021 | 56,718 | 688,579 (1%) | 0% | 6.8 | 387,384 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 68.78 per share. | 05 Feb 2021 | 881 | 631,861 (1%) | 0% | 68.8 | 60,595 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 67.86 per share. | 05 Feb 2021 | 14,018 | 632,742 (1%) | 0% | 67.9 | 951,261 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 67.18 per share. | 05 Feb 2021 | 8,043 | 646,760 (1%) | 0% | 67.2 | 540,329 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 60,000 | 160,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 67,060 | 17,940 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 110,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 72.00 per share. | 01 Feb 2021 | 30,998 | 584,601 (1%) | 0% | 72 | 2,231,856 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.78 per share. | 01 Feb 2021 | 50,000 | 615,599 (1%) | 0% | 22.8 | 1,139,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.04 per share. | 01 Feb 2021 | 5,475 | 565,599 (1%) | 0% | 65.0 | 356,094 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.10 per share. | 01 Feb 2021 | 16,640 | 571,074 (1%) | 0% | 64.1 | 1,066,624 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.30 per share. | 01 Feb 2021 | 11,100 | 587,714 (1%) | 0% | 63.3 | 702,630 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.78 per share. | 01 Feb 2021 | 60,000 | 598,814 (1%) | 0% | 22.8 | 1,366,800 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.03 per share. | 01 Feb 2021 | 3,260 | 538,814 (1%) | 0% | 65.0 | 211,998 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.09 per share. | 01 Feb 2021 | 9,432 | 542,074 (1%) | 0% | 64.1 | 604,497 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.29 per share. | 01 Feb 2021 | 6,448 | 551,506 (1%) | 0% | 63.3 | 408,094 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 01 Feb 2021 | 30,000 | 557,954 (1%) | 0% | 18.3 | 549,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.02 per share. | 01 Feb 2021 | 693 | 527,954 (1%) | 0% | 65.0 | 45,059 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.16 per share. | 01 Feb 2021 | 3,497 | 528,647 (1%) | 0% | 64.2 | 224,368 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.24 per share. | 01 Feb 2021 | 1,709 | 532,144 (1%) | 0% | 63.2 | 108,077 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Feb 2021 | 10,000 | 533,853 (1%) | 0% | 13.9 | 138,800 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 01 Feb 2021 | 8,827 | 523,853 (1%) | 0% | 65 | 573,755 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.13 per share. | 01 Feb 2021 | 26,058 | 532,680 (1%) | 0% | 64.1 | 1,671,100 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.32 per share. | 01 Feb 2021 | 16,750 | 558,738 (1%) | 0% | 63.3 | 1,060,610 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 01 Feb 2021 | 100,000 | 575,488 (1%) | 0% | 6.8 | 683,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 27,500 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 85,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 100,000 | 125,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 73.00 per share. | 01 Feb 2021 | 36,858 | 614,803 (1%) | 0% | 73 | 2,690,634 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Feb 2021 | 67,060 | 651,661 (1%) | 0% | 13.9 | 930,793 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 64.16 per share. | 01 Feb 2021 | 8,366 | 106,703 (0%) | 0% | 64.2 | 536,763 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 63.34 per share. | 01 Feb 2021 | 6,617 | 115,069 (0%) | 0% | 63.3 | 419,121 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Feb 2021 | 33,000 | 121,686 (0%) | 0% | 13.9 | 458,040 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 65.01 per share. | 01 Feb 2021 | 5,312 | 88,686 (0%) | 0% | 65.0 | 345,333 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 64.11 per share. | 01 Feb 2021 | 15,594 | 93,998 (0%) | 0% | 64.1 | 999,731 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 63.31 per share. | 01 Feb 2021 | 10,476 | 109,592 (0%) | 0% | 63.3 | 663,236 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 01 Feb 2021 | 10,000 | 113,876 (0%) | 0% | 14.6 | 145,800 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 65.05 per share. | 01 Feb 2021 | 2,827 | 103,876 (0%) | 0% | 65.0 | 183,896 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 01 Feb 2021 | 66,000 | 120,068 (0%) | 0% | 6.8 | 450,780 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 61,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 33,000 | 72,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 66,000 | 39,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 65.07 per share. | 01 Feb 2021 | 755 | 108,409 (0%) | 0% | 65.1 | 49,128 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 64.18 per share. | 01 Feb 2021 | 2,386 | 109,164 (0%) | 0% | 64.2 | 153,133 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 63.44 per share. | 01 Feb 2021 | 2,326 | 111,550 (0%) | 0% | 63.4 | 147,561 | Common Stock |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.78 per share. | 20 Jan 2021 | 20,000 | 30,000 (0%) | 0% | 13.8 | 275,600 | Common Stock |
| Fred E. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 20,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 17 Dec 2020 | 31,764 | 36,764 (0%) | 0% | 18 | 571,752 | Common Stock |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 31,764 | 0 | - | - | Stock Option (right to buy) | |
| Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 54.33 per share. | 17 Dec 2020 | 21,336 | 5,000 (0%) | 0% | 54.3 | 1,159,185 | Common Stock |
| Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 53.69 per share. | 17 Dec 2020 | 45,450 | 26,336 (0%) | 0% | 53.7 | 2,440,211 | Common Stock |
| Perry A. Karsen | Director | Sale of securities on an exchange or to another person at price $ 52.52 per share. | 17 Dec 2020 | 21,978 | 71,786 (0%) | 0% | 52.5 | 1,154,285 | Common Stock |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 17 Dec 2020 | 19,000 | 93,764 (0%) | 0% | 15.8 | 299,820 | Common Stock |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.98 per share. | 17 Dec 2020 | 19,000 | 74,764 (0%) | 0% | 26.0 | 493,620 | Common Stock |
| Perry A. Karsen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.35 per share. | 17 Dec 2020 | 19,000 | 55,764 (0%) | 0% | 14.4 | 272,650 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 37.73 per share. | 01 Dec 2020 | 1,585 | 50,487 (0%) | 0% | 37.7 | 59,802 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 5,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 39.46 per share. | 01 Dec 2020 | 257 | 48,708 (0%) | 0% | 39.5 | 10,141 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 38.49 per share. | 01 Dec 2020 | 1,522 | 48,965 (0%) | 0% | 38.5 | 58,582 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Dec 2020 | 5,000 | 52,072 (0%) | 0% | 13.9 | 69,400 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 27 Nov 2020 | 15,000 | 467,352 (0%) | 0% | 38 | 570,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2020 | 20,000 | 200,000 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2020 | 15,000 | 57,500 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.00 per share. | 27 Nov 2020 | 20,000 | 467,352 (0%) | 0% | 39 | 780,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 27 Nov 2020 | 20,000 | 487,352 (0%) | 0% | 14.6 | 291,600 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 27 Nov 2020 | 15,000 | 482,352 (0%) | 0% | 18.3 | 274,500 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2020 | 50,000 | 225,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 25 Nov 2020 | 50,000 | 467,352 (0%) | 0% | 36 | 1,800,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 25 Nov 2020 | 50,000 | 517,352 (1%) | 0% | 6.8 | 341,500 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 16 Nov 2020 | 20,000 | 467,352 (0%) | 0% | 34 | 680,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 16 Nov 2020 | 20,000 | 487,352 (0%) | 0% | 14.6 | 291,600 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 20,000 | 220,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 16 Nov 2020 | 624 | 47,072 (0%) | 0% | 35 | 21,840 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 16 Nov 2020 | 848 | 47,696 (0%) | 0% | 18.3 | 15,518 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 16 Nov 2020 | 414 | 46,848 (0%) | 0% | 35 | 14,490 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 16 Nov 2020 | 562 | 47,262 (0%) | 0% | 18.3 | 10,285 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 34.51 per share. | 16 Nov 2020 | 3,595 | 46,700 (0%) | 0% | 34.5 | 124,063 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 16 Nov 2020 | 10,000 | 52,315 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 33.75 per share. | 16 Nov 2020 | 2,020 | 50,295 (0%) | 0% | 33.8 | 68,175 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 848 | 71,090 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 562 | 71,938 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 10,000 | 105,117 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 04 Nov 2020 | 50,000 | 467,352 (0%) | 0% | 26 | 1,300,000 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 50,000 | 275,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 04 Nov 2020 | 50,000 | 517,352 (1%) | 0% | 6.8 | 341,500 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 04 Nov 2020 | 5,000 | 45,679 (0%) | 0% | 13.9 | 69,400 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 5,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 04 Nov 2020 | 3,364 | 42,315 (0%) | 0% | 28 | 94,192 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 15 Oct 2020 | 156 | 40,679 (0%) | 0% | 24.6 | 3,830 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 15 Oct 2020 | 10,000 | 46,294 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 24.19 per share. | 15 Oct 2020 | 5,459 | 40,835 (0%) | 0% | 24.2 | 132,053 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 10,000 | 115,117 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2020 | 5,000 | 325,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 07 Oct 2020 | 5,000 | 467,352 (0%) | 0% | 21.8 | 109,150 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 07 Oct 2020 | 5,000 | 472,352 (0%) | 0% | 6.8 | 34,150 | Common Stock |
| John F. Crowley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2020 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 21.04 per share. | 15 Sep 2020 | 5,615 | 36,294 (0%) | 0% | 21.0 | 118,140 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2020 | 10,000 | 125,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 15 Sep 2020 | 10,000 | 41,909 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 01 Sep 2020 | 5,000 | 467,352 (0%) | 0% | 21.8 | 109,150 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 5,000 | 330,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 01 Sep 2020 | 5,000 | 472,352 (0%) | 0% | 6.8 | 34,150 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 18 Aug 2020 | 5,615 | 31,909 (0%) | 0% | 21 | 117,915 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2020 | 10,000 | 135,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 18 Aug 2020 | 10,000 | 37,524 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 06 Aug 2020 | 5,000 | 467,352 (0%) | 0% | 21.8 | 109,150 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 5,000 | 335,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 06 Aug 2020 | 5,000 | 472,352 (0%) | 0% | 6.8 | 34,150 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 15 Jul 2020 | 10,000 | 33,139 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2020 | 10,000 | 145,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 22.70 per share. | 15 Jul 2020 | 5,615 | 27,524 (0%) | 0% | 22.7 | 127,461 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 5,000 | 340,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 01 Jul 2020 | 5,000 | 467,352 (0%) | 0% | 21.8 | 109,150 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 01 Jul 2020 | 5,000 | 472,352 (0%) | 0% | 6.8 | 34,150 | Common Stock |
| Fred E. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 16 Jun 2020 | 5,615 | 22,282 (0%) | 0% | 21 | 117,915 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 10,000 | 155,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 16 Jun 2020 | 10,000 | 27,897 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 03 Jun 2020 | 5,000 | 467,352 (0%) | 0% | 21.8 | 109,150 | Common Stock |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2020 | 5,000 | 345,234 | - | - | Stock Option (right to buy) | |
| John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 03 Jun 2020 | 5,000 | 472,352 (0%) | 0% | 6.8 | 34,150 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 26 May 2020 | 10,000 | 285,722 (0%) | 0% | 6.8 | 68,300 | Common Stock |
| Jose E. Rivera | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2020 | 10,000 | 165,117 | - | - | Stock Option (right to buy) | |
| Jose E. Rivera | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 26 May 2020 | 5,615 | 280,107 (0%) | 0% | 21.2 | 119,094 | Common Stock |
| David Lebwohl | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 340,000 | 340,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Goddard | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2020 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) |